Agios Pharmaceuticals (AGIO) Common Equity (2012 - 2026)

Agios Pharmaceuticals has reported Common Equity for 15 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 24.37% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (down 24.37% YoY), and the FY2025 full-year result was $1.2 billion, down 22.57% from the prior year.
• Common Equity for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
• The five-year high for Common Equity was $1.6 billion in Q3 2024, with the low at $660.5 million in Q2 2024.
• Historically, Common Equity has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2026.
• Annual changes were most pronounced in 2022 — Common Equity slumped 47.43% — and 2025, when it jumped 107.35%.
• Agios Pharmaceuticals' Common Equity stood at $1.1 billion in 2022, then decreased by 26.33% to $811.0 million in 2023, then jumped by 90.0% to $1.5 billion in 2024, then declined by 22.57% to $1.2 billion in 2025, then retreated by 7.04% to $1.1 billion in 2026.
• The last three Common Equity figures came in at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.